Patient Characteristics
| Characteristic | Parameter | Data |
| Age at baseline scan (y) | 69.8 (46–76) | |
| Sex | Female | 2 (20%) |
| Male | 8 (80%) | |
| Primary location | Small bowel | 4 (40%) |
| Pancreas | 3 (30%) | |
| Large bowel | 1 (10%) | |
| Bronchial | 1 (10%) | |
| Gastric | 1 (10%) | |
| Liver involvement with metastatic disease | <25% | 3 (30%) |
| 25%–50% | 4 (40%) | |
| 51%–70% | 3 (30%) | |
| Extrahepatic disease | Yes | 7 (70%) |
| No | 3 (30%) | |
| Metastatic locations | Liver | 10 (100%) |
| Lung | 1 (10%) | |
| Bone | 3 (30%) | |
| Other | 7 (70%) | |
| Previous treatments | Surgery | 6 (90%) |
| SSA therapy | 10 (100%) | |
| Chemotherapy | 4 (40%) | |
| Targeted agents | 2 (20%) | |
| Liver-directed | ||
| TAE/TACE | 3 (30%) | |
| 90Y-SIRT | 2 (20%) | |
| Lines of prior therapy per patient | 4 (1–6) | |
| Tumor grade | 1 (Ki-67 < 3%) | 4 (40%) |
| 2 (Ki-67 = 3%–20%) | 5 (50%) | |
| 3 (Ki-67 > 20%) | 1 (10%) | |
| Administered dose of 90Y-DOTATOC | mCi | 95.95 (83.1–102.1) |
| MBq | 3,550 (3,074–3,778) |
TAE/TACE = transarterial embolization/transarterial chemoembolization; SIRT = selective internal radiation therapy.
Qualitative data are numbers followed by percentages in parentheses; continuous data are median followed by range in parentheses.